Phase 3 clinical trials in people with T2DM (SURPASS) and obesity (SURMOUNT) (16–21) support early findings and demonstrate advantages of tirzepatide in glycemia and weight management compared to GLP-1R monotherapies. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.